Arcutis Biotherapeutics, Inc.: Form 10-K for the period ended Dec 31, 2025
Filed with the SEC on Feb 25, 2026 and accepted by EDGAR at Feb 25, 2026, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $376.1m | us-gaap:Revenues |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $36.7m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2025-01-01 to 2025-12-31 | $77.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2025-01-01 to 2025-12-31 | $274.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$12.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $12.1m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$16.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 127,234,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$5.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $686.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $42.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $411.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $433.0m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $129.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $243.5m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $108.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-12-31 | $1.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-12-31 | $189.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001787306-26-000018. Last ingested by Listed: Oct 28, 2026, 09:04 ET. Listed shows no prices and gives no investment advice.